<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588611</url>
  </required_header>
  <id_info>
    <org_study_id>RE-20180628</org_study_id>
    <nct_id>NCT03588611</nct_id>
  </id_info>
  <brief_title>Reduce Bolus Injection of Bivalirudin</brief_title>
  <official_title>The Noninferiority and Safety of Bivalirudin Between REDUCEd and Standard BOLUSin Percutaneous Coronary Intervention Patients Stratified by Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Yaling, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are fewer studies on the bleeding risk of the currently administered bivalirudin bolus
      injection dose and the safety of bivalirudin in patients with CKD. A non-inferiority,
      randomized, stratified controlled trial study has been conducted to evaluate the
      non-inferiority and safety of the low dose (80%) bolus injections of bivalirudin in patients
      with or without CKD.This study will provide a safe, effective and economical anticoagulation
      strategy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve of the ACT values for both groups</measure>
    <time_frame>During operation</time_frame>
    <description>We will record the ACT values of 0 min, 5 min, 10 min, and 30 min after bolus injection of bivalirudin in patients undergoing PCI,and the area of the closed pattern under the curve will be calculated, and the anticoagulant effect of bivalirudin will be evaluated by the area under the ACT line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding and ischaemic events during hospitalization after surgery .</measure>
    <time_frame>In hospital</time_frame>
    <description>Bleeding events are defined as BARC grade 1-5. Ischemic events are defined as stroke, nonfatal myocardial reinfarction, ischemic-driven target vessel revascularization.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Low dose group with eGFR ≥60ml/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose group with eGFR ≥ 60ml/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose group with eGFR &lt;60ml/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm, we will choose the patients who's eGFR ＜60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group with eGFR &lt;60ml/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, we will choose the patients who's eGFR ＜60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;</description>
    <arm_group_label>Standard dose group with eGFR &lt;60ml/min</arm_group_label>
    <arm_group_label>Standard dose group with eGFR ≥ 60ml/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;</description>
    <arm_group_label>Low dose group with eGFR &lt;60ml/min</arm_group_label>
    <arm_group_label>Low dose group with eGFR ≥60ml/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 Age 18 to 80 years old; 2 Medically judge to require coronary angiography; 3
             Patients agree to use bivalirudin 4 Patients signe informed consent.

        Exclusion Criteria:

          -  1.Cardiogenic shock; 2.Thrombolytic therapy administered before randomization or any
             anticoagulant administered within 48 hours of randomization; 3.Active or recent major
             bleeding or bleeding predisposition; 4.Major surgery within 1 month; 5.Clinical
             syndrome suspicious for aortic dissection, pericarditis, or endocarditis; blood
             pressure higher than 180/110 mm Hg; 6.Known hemoglobin less than 10 g/dL,platelet
             count less than 100 × 109/L, aminotransferase level greater than 3 × the upper limit
             of normal; 7.History of heparin-induced thrombocytopenia; 8.Ellergy to any of the
             study drugs or devices; 9.Eregnancy or lactation; 10.Any condition making PCI
             unsuitable or that might interfere with study adherence; 11.Patient unwilling or
             unable to provide written informed consent 12. Researchers think it is not suitable to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wang xiaozeng, Dr.</last_name>
    <phone>+86 13309885930</phone>
    <email>wxiaozeng@163.com</email>
  </overall_contact>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling, MD</investigator_full_name>
    <investigator_title>The noninferiority and safety of bivalirudin between REDUCEd and standard BOLUSin percutaneous coronary intervention patients stratified by renal function</investigator_title>
  </responsible_party>
  <keyword>bivalirudin</keyword>
  <keyword>bolus injection</keyword>
  <keyword>activated clotting time</keyword>
  <keyword>Renal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

